ReviewFrontiers in immunology2026
Inborn errors of immunity in Low German Mennonite communities in Mexico: a case series and narrative literature review.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inborn errors of immunity (IEI) comprise a genetically heterogeneous group of disorders with increased prevalence in consanguineous and endogamous populations due to founder effects. Low German Mennonite (LGM) communities in Mexico represent a high-risk population characterized by genetic isolation and an increased frequency of autosomal recessive conditions. Although IEI have been reported in LGM populations from Canada and Europe, systematic data from Mexican LGM communities remain limited. This study describes four novel clinical cases of IEI in LGM patients evaluated at two tertiary referral centers in Mexico and contextualizes these findings within a comprehensive review of previously reported IEI in this population. Methods: A retrospective case series was conducted at two tertiary pediatric referral centers in Mexico between 2020 and 2025, including four patients from LGM communities with clinically and/or genetically confirmed IEI. Clinical, immunological, and genetic data were extracted from medical records. Genetic diagnoses, when available, were established using next-generation sequencing or whole-exome sequencing, with variant classification according to ACMG criteria. A narrative literature search was performed in PubMed, Embase, SciELO, and Web of Science to identify previously reported IEI cases in LGM populations. Results: Four patients with distinct IEI were identified: one with glucose-6-phosphatase catalytic subunit 3 (G6PC3) deficiency, one with X-linked agammaglobulinemia (XLA) due to a pathogenic variant in the Bruton tyrosine kinase (BTK) gene, and two with severe combined immunodeficiency (SCID). All patients required disease-specific therapy, including granulocyte colony-stimulating factor, immunoglobulin replacement, and/or hematopoietic cell transplantation. The literature review identified a broad spectrum of IEI in LGM populations, including cellular and humoral immunodeficiencies, phagocyte disorders, DNA repair defects, autoinflammatory conditions, and bone marrow failure syndromes. Conclusions: This exploratory case series contributes to the growing body of evidence on IEI in LGM populations and highlights the potential impact of founder variants in this community. Given the small sample size and retrospective design, generalization of these findings requires prospective, population-based validation. Early diagnosis through newborn screening, accessible genetic testing, and timely clinical intervention remains essential to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.